$8.53
6.49% yesterday
NYSE, May 08, 10:10 pm CET
ISIN
US03969F1093
Symbol
RCUS

Arcus Biosciences Target price 2025 - Analyst rating & recommendation

Arcus Biosciences Classifications & Recommendation:

Buy
85%
Hold
15%

Arcus Biosciences Price Target

Target Price $28.82
Price $8.53
Potential
Number of Estimates 11
11 Analysts have issued a price target Arcus Biosciences 2026 . The average Arcus Biosciences target price is $28.82. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 11 Analysts recommend Arcus Biosciences to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arcus Biosciences stock has an average upside potential 2026 of . Most analysts recommend the Arcus Biosciences stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 258.00 133.91
120.51% 48.10%
EBITDA Margin -116.28% -331.50%
58.01% 185.09%
Net Margin -128.89% -351.86%
65.69% 173.00%

10 Analysts have issued a sales forecast Arcus Biosciences 2025 . The average Arcus Biosciences sales estimate is

$134m
Unlock
. This is
5.03% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$200m 41.84%
Unlock
, the lowest is
$88.0m 37.59%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $258m 120.51%
2025
$134m 48.10%
Unlock
2026
$169m 26.05%
Unlock
2027
$240m 42.47%
Unlock
2028
$521m 116.75%
Unlock
2029
$824m 58.12%
Unlock

4 Analysts have issued an Arcus Biosciences EBITDA forecast 2025. The average Arcus Biosciences EBITDA estimate is

$-444m
Unlock
. This is
4.20% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-384m 9.87%
Unlock
, the lowest is
$-539m 26.45%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-300m 7.41%
2025
$-444m 47.97%
Unlock
2026
$-471m 6.17%
Unlock
2027
$-442m 6.14%
Unlock

EBITDA Margin

2024 -116.28% 58.01%
2025
-331.50% 185.09%
Unlock
2026
-279.22% 15.77%
Unlock
2027
-183.96% 34.12%
Unlock

11 Arcus Biosciences Analysts have issued a net profit forecast 2025. The average Arcus Biosciences net profit estimate is

$-471m
Unlock
. This is
6.19% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-355m 20.05%
Unlock
, the lowest is
$-606m 36.52%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-333m 24.34%
2025
$-471m 41.69%
Unlock
2026
$-467m 0.90%
Unlock
2027
$-404m 13.54%
Unlock
2028
$-122m 69.88%
Unlock
2029
$71.0m 158.34%
Unlock

Net Margin

2024 -128.89% 65.69%
2025
-351.86% 173.00%
Unlock
2026
-276.64% 21.38%
Unlock
2027
-167.88% 39.31%
Unlock
2028
-23.33% 86.10%
Unlock
2029
8.61% 136.91%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.14 -4.45
24.34% 41.72%
P/E negative
EV/Sales negative

11 Analysts have issued a Arcus Biosciences forecast for earnings per share. The average Arcus Biosciences EPS is

$-4.45
Unlock
. This is
6.21% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.35 20.05%
Unlock
, the lowest is
$-5.72 36.52%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.14 24.34%
2025
$-4.45 41.72%
Unlock
2026
$-4.41 0.90%
Unlock
2027
$-3.81 13.61%
Unlock
2028
$-1.15 69.82%
Unlock
2029
$0.67 158.26%
Unlock

P/E ratio

Current -2.04 46.03%
2025
-1.92 5.88%
Unlock
2026
-1.93 0.52%
Unlock
2027
-2.24 16.06%
Unlock
2028
-7.43 231.70%
Unlock
2029
12.73 271.33%
Unlock

Based on analysts' sales estimates for 2025, the Arcus Biosciences stock is valued at an EV/Sales of

-0.25
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -0.24 103.56%
2025
-0.25 5.17%
Unlock
2026
-0.20 20.68%
Unlock
2027
-0.14 29.77%
Unlock
2028
-0.06 53.91%
Unlock
2029
-0.04 36.73%
Unlock

P/S ratio

Current 6.41 47.51%
2025
6.75 5.30%
Unlock
2026
5.35 20.67%
Unlock
2027
3.76 29.81%
Unlock
2028
1.73 53.86%
Unlock
2029
1.10 36.76%
Unlock

Current Arcus Biosciences Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Goldman Sachs
Locked
Locked
Locked May 08 2025
Wells Fargo
Locked
Locked
Locked May 07 2025
Barclays
Locked
Locked
Locked Apr 23 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 26 2025
B of A Securities
Locked
Locked
Locked Feb 19 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 18 2025
Morgan Stanley
Locked
Locked
Locked Feb 18 2025
Analyst Rating Date
Locked
Goldman Sachs:
Locked
Locked
May 08 2025
Locked
Wells Fargo:
Locked
Locked
May 07 2025
Locked
Barclays:
Locked
Locked
Apr 23 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 26 2025
Locked
B of A Securities:
Locked
Locked
Feb 19 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 18 2025
Locked
Morgan Stanley:
Locked
Locked
Feb 18 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today